Cord Blood Treg Expansion With One-Step Magnetic Sorting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding regulatory T cells (Tregs) from cord blood are inefficient, requiring multiple steps and lengthy processes, limiting their production to meet the needs of clinical patients.
Innovation Solution
An optimized method involving one-step magnetic sorting and a specific culture medium for expanding Tregs, including CD4+CD25+CD127− Tregs, with a total culture time of 40 to 50 days, using a serum-free medium and recombinant interleukin-2, to enhance production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional in vitro expansion method is used, then Tregs can be obtained with basic functionality, but the expansion fold is only about 100 and the process takes 14-21 days, which is insufficient for clinical patient needs
Solution Approach 1:
The patent changes key culture parameters including using a specialized expansion medium containing IL-2, anti-CD3, and anti-CD28 factors; optimizing cell density from 1×10^6 to 5×10^6 cells/mL; and extending culture duration to 40-50 days with periodic medium changes. These parameter changes enable achieving expansion folds of 10,000-100,000 while maintaining Treg functionality.
Solution Approach 2:
The patent performs preliminary magnetic bead sorting to highly purify Tregs (CD4+CD25+CD127-) before expansion, ensuring >90% purity. This preliminary purification action removes non-Treg cells that would compete for resources and potentially contaminate the final product, enabling more efficient and scalable expansion for multiple patients.
2Productivity
If conventional expansion method is used, then the process is simpler, but it requires multiple steps and cannot meet large-scale production demands
Solution Approach 1:
The patent combines multiple functions into integrated processes: magnetic bead sorting simultaneously achieves purification and enrichment of Tregs; the expansion medium combines multiple growth factors (IL-2, anti-CD3, anti-CD28) into a single formulation; and the culture system integrates periodic medium changes with cell passage operations. This merging reduces the number of separate processing steps while enabling large-scale production.
Solution Approach 2:
The patent segments the expansion process into distinct phases: initial adaptation phase (days 1-3), exponential expansion phase (days 4-35), and harvesting phase (days 36-50). Each phase has optimized conditions and can be independently controlled, allowing scalability from small to large production volumes while maintaining process simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the expansion generation number and quantity of Tregs, maintaining high viability and functional integrity, meeting clinical demands.
Implementation Method 1
transferring the cord blood-derived Treg-containing suspension into a sterile tube matching with a magnetic pole, and magnetically sorting CD4+CD25+CD127− Tregs out
Data Source
AI summary
An optimized method for expansion and large-scale production of regulatory T cells (Tregs) includes the following steps: preparing a cord blood-derived Treg-containing suspension; transferring the cord blood-derived Treg-containing suspension into a sterile tube matching with a magnetic pole, and magnetically sorting CD4+CD25+CD127− Tregs out; adding an expansion culture medium to Tregs carrying magnetic beads, conducting a primary culture for 1 d to 2 d, and conducting a subculture once every 1 d to 3 d, where a total culture time is 40 d to 50 d. Through one-step sorting, the method achieves very prominent cell expansion effects (shortened time and high cell viability), and increases an effective expansion time to 40 d to 50 d from 18 d. In addition, an expansion effect will not be gradually deteriorated. Thus, the method greatly increases the expansion generation number and the quantity of Tregs, and can meet the needs of clinical patients.